{
    "clinical_study": {
        "@rank": "75815", 
        "brief_summary": {
            "textblock": "For patients with relapsed and refractory aggressive non-Hodgkin's lymphoma"
        }, 
        "brief_title": "A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma", 
        "completion_date": {
            "#text": "April 2004", 
            "@type": "Actual"
        }, 
        "condition": "Non-Hodgkin's Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Aggression", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION:\n\n          -  Bidimensionally measurable current/refractory aggressive NHL (Diffuse lg cell,\n             diffuse mixed cell, follicular lg non-cleaved, immunoblastic, Ki-1+ALCL, peripheral\n             T-cell lymphoma, mantle cell lymphoma & transformed lymphoma.)\n\n          -  No more than 3 prior treatment regimens.  No anti-lymphoma therapy within the past 3\n             weeks.\n\n          -  Not be eligible for treatment of a higher priority.\n\n          -  Performance status <2 Zubrod, > 60 Karnofsky.\n\n          -  Good marrow reserve: ANC>1.5 x 10(9)/L, platelets > 100 x 10(9)/L.\n\n          -  Bilirubin <1.5mg/dL, SGOT, SGPT < 2 x normal values.\n\n          -  Serum creatinine < 1.8 mg/dL.\n\n          -  Age > 18 yrs.\n\n          -  Signed informed consent.\n\n          -  Life expectancy of > 12 weeks.\n\n          -  No prior Taxane (paclitaxel or docetaxel), topotecan, or CPT-11.\n\n          -  No prior stem cell or bone marrow transplantation.\n\n          -  No prior second malignancies except for basal cell carcinoma of the skin.\n\n        EXCLUSION:\n\n          -  Active or prior history of CNS lymphoma.\n\n          -  Serious intercurrent medical illnesses requiring  hospitalization.\n\n          -  History of primary/secondary immunodeficiency (other than related to the malignant\n             lymphoma because treatment is dependent on a functional immune system) or patients\n             taking immunosuppressive drugs (systemic corticosteroids).\n\n          -  Prior exposure to Filgrastim-SD/01.\n\n          -  Women who are pregnant or lactating.\n\n          -  Participation in another clinical trial.\n\n          -  Positive HIV antibody.\n\n          -  History of prior sensitivity to E. coli derived products (such as\n             filgrastim/neupogen)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 31, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00038545", 
            "org_study_id": "DM01-008"
        }, 
        "intervention": [
            {
                "intervention_name": "Filgrastim SD/01", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Topotecan", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Paclitaxel", 
                "Topotecan", 
                "Lenograstim"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "LYMPHOMA", 
            "NON-HODGKINS", 
            "AGGRESSIVE", 
            "RELAPSED AND REFRACTORY"
        ], 
        "lastchanged_date": "January 20, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "UT MD Anderson Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Patients With Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma", 
        "overall_official": {
            "affiliation": "UT MD Anderson Cancer Center", 
            "last_name": "Anas Younes, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2004", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00038545"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "M.D. Anderson Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "M.D. Anderson Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2001", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2012"
    }, 
    "geocoordinates": {
        "UT MD Anderson Cancer Center": "29.76 -95.369"
    }
}